Chuangsheng Group-B (06628): Chuangsheng Pharmaceutical announced updated efficacy data on Osemitamab triple therapy for first-line treatment of gastric or gastroesophageal adenocarcinoma in ESMO Asia (Transtar102)

Zhitong Finance App News, Chuangsheng Group-B (06628) issued an announcement. The company's board of directors is pleased to announce that the phase I/II clinical trial (Transtar102) G cohort of osemitamab combined with navulimab and capox as first-line treatment for gastric or gastroesophageal adenocarcinoma (Transtar102) is based on updated efficacy analysis of CLDN18.2 and PD-L1 expression. The findings were presented as a poster (abstract number: #299P) at the European Society of Medical Oncology Asian Annual Meeting 2025 (ESMO Asia Congress 2025) in Singapore.

The new analytical results further confirm the encouraging clinical benefits shown by the osemitamab triple therapy. After 25.8 months of median follow-up, the median progression-free survival (mPFS) reached 16.6 months, the objective remission rate (ORR) was 68%, and the median duration of remission (MdOR) was 18 months in 26 cases with CLDN18.2 expression ≥ 40%, ≥2+ and known PD-L1 CPS. It is worth noting that in the PD-L1 CPS<1 and ≥1 subgroups, patients with higher CLDN18.2 expression were superior to those with lower expression of CLDN18.2. This indicates that the potential therapeutic benefit of osemitamab was not affected by PD-L1 expression level and was consistent.

The safety characteristics are consistent with data previously published at the ASCO 2025 conference.

“Exploratory efficacy analysis continues to show that osemitamab combined with standard treatment has good clinical benefits,” said Professor Shen Lin, director of the Department of Gastroenterological Oncology and Phase I clinical trial ward at Peking University Cancer Hospital and the lead researcher in this study. “The consistent benefit consistency of patients in different PD-L1 subgroups is particularly noteworthy, which indicates that this treatment is expected to bring clinically significant benefit improvements to patients with advanced gastric or gastroesophageal adenocarcinoma.”

“We are pleased to see that this study continues to show strong clinical benefit signals, further confirming osemitamab's potential to bring substantial benefits to patients, who are in urgent need of more effective treatment options.” Dr. Qi Chuan, Executive Vice President of Global Clinical Development at Chuangsheng Pharmaceutical, said, “Furthermore, updated data continues to confirm that osemitamab combined with navulizumab and capox have good safety and tolerability as a first-line treatment for advanced gastric or gastroesophageal adenocarcinoma.”